NCT01290913

Xolair Enhances Oral Desensitization in Peanut Allergic Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Lynda Schneider · Academic / Other
• Sex: All
• Age: 7 Years – 25 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.

Detailed description

We hypothesize that pretreatment with anti-IgE mAb will greatly reduce the side effects and allergic reactions that occur during oral desensitization to peanut and will enhance the development of oral tolerance in patients with severe peanut allergy. We will follow the patients for 5 years following study completion.

Conditions

• Peanut Allergy

Interventions

Type	Name	Description
DRUG	Omalizumab	Omalizumab is an antibody that helps decrease allergic responses in the body

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2011-02-07
• Last updated: 2015-04-07
• Results posted: 2015-02-20

Locations

1 site across 1 country: United States